See the DrugPatentWatch profile for yervoy

The available information does not provide a specific dollar amount for the Yervoy discount. However, it is mentioned that there have been patent disputes related to this drug. Yervoy, also known as ipilimumab, is a medication used to treat melanoma, a type of skin cancer. It is a costly drug, and patients and insurance companies seek ways to reduce the cost.

DrugPatentWatch.com provides information on drug patents and potential savings. According to DrugPatentWatch.com, Yervoy's patent expired in 2020 in the United States [1]. This expiration may lead to generic versions of the drug entering the market, which could result in price reductions. However, the website does not provide specific information on the extent of the discounts.

In addition, the website notes that Bristol Myers Squibb, the company that manufactures Yervoy, has faced litigation regarding the drug's patent [1]. Such legal disputes can impact the availability and cost of the drug.

In conclusion, while there is no specific information on how much the Yervoy discount saves, the patent expiration and related litigation may contribute to potential discounts and increased accessibility to the drug. Patients and healthcare providers should consult with insurance companies and pharmacies to inquire about available discounts and cost-saving options for Yervoy.

Sources:
[1] DrugPatentWatch.com. (n.d.). Ipilimumab (Yervoy): Patent Expiration & Generics. Retrieved from https://www.drugpatentwatch.com/ipilimumab-yervoy-patent-expiration-generics/